Las inundaciones en La Plata, Berisso y Ensenada. Análisis de riesgos y estrategias de intervención

El trabajo presenta parte de dos proyectos de investigación en desarrollo que indagan y caracterizan los riesgos por inundación en el caso de estudio y las estrategias para su mitigación o adaptación. Se parte de entender que los conflictos hídricos en torno a las inundaciones urbanas son de naturaleza multicausal, pero preponderantemente responden a los efectos del cambio climático. Este hecho alerta sobre la necesidad de modificar la racionalidad del manejo de esta situación. En La Plata, Berisso y Ensenada (Gran La Plata, en adelante GLP-1.162 km2), han sido múltiples los eventos en los últimos cien años. Pero en la última década se han agudizado, hasta llegar a la situación del 2 y 3 de abril del 2013 con una precipitación extraordinaria de 400 milímetros, (lloviendo 313 mm en 6 horas), cuando lo ordinario para el mes de abril es 111 mm, lo que dejó un resultado catastrófico con 89 muertes.Trabajo publicado en Acta Bioquímica Clínica Latinoamericana; no. 52, supl. 2, parte II, diciembre de 2018.Universidad Nacional de La Plat

Hypoglycaemia in clinical diabetes

xii+346hlm.;25c

Supplementary Material for: Selected β-glucans act as immune-training agents by improving anti-mycobacterial activity in human macrophages - a pilot study.

Epigenetic reprogramming of innate immune cells by β-glucan in a process called trained immunity, leads to an enhanced host response to a secondary infection. β-glucans are structural components of plants, algae, fungi and bacteria and thus recognized as non-self by human macrophages. We selected the β-glucans curdlan from Alcaligenes faecalis, WGP dispersible from Saccharomyces cerevisiae, and β-glucan-rich culture supernatant of Alternaria and investigated whether they could produce trained immunity effects leading to an increased control of virulent Mycobacterium tuberculosis. We observed a significant M. tuberculosis growth-reduction in macrophages trained with curdlan and Alternaria, which also correlated with increased IL-6 and IL-1β release. WGP dispersible-trained macrophages were stratified into ‘non responders’ and ‘responders’, according to their ability to control M. tuberculosis, with ‘responders’ producing higher IL-6 levels. The addition of neutrophils to infected macrophage cultures further enhanced macrophage control of virulent M. tuberculosis, but not in a stimuli-dependent manner. Pathway enrichment analysis of DNA methylome data also highlighted hypomethylation of genes in pathways associated with signaling and cellular reorganization and motility, and ‘responders’ to WGP-training were enriched in the interferon-gamma signaling pathway. This study adds evidence that certain β-glucans show promise as immune training agents

Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial

We assessed the safety and efficacy of 2 injections of platelet-rich plasma for treating mild to moderate erectile dysfunction by conducting a prospective, randomized, double-blind, placebo-controlled clinical trial. Men with mild to moderate erectile dysfunction (International Index of Erectile Function scores 11-25) were randomized to receive either 2 injections of platelet-rich plasma or placebo separated by 1 month. Primary outcome was percentage of men meeting minimum clinically important difference at 1 month after the second injection. Secondary outcomes were change in International Index of Erectile Function at 1, 3, and 6 months, and changes in penile vascular parameters and adverse events at 6 months. We randomized 61 men: 28 into platelet-rich plasma and 33 into placebo. There was no difference between groups in percentage of men meeting minimum clinically important difference at 1 month: 14 (58.3%) in platelet-rich plasma vs 15 (53.6%) in placebo ( = .730). Mean International Index of Erectile Function-Erectile Function domain changed from 17.4 (95% CI 15.8-19.0) to 21 (17.9-24.0) at 1 month in men receiving platelet-rich plasma, vs 18.6 (17.3-19.8) to 21.6 (19.1-24.1) in the placebo group; however, there was no significant difference between groups ( = .756). There were no major adverse events and only 1 minor adverse event in each group. There were no changes in penile Doppler parameters from baseline to 6 months. The results of our prospective, double-blind, randomized, placebo-controlled clinical trial suggest that 2 injections of intracavernosal platelet-rich plasma separated by 1 month in men with mild to moderate erectile dysfunction is safe, but we found no difference in efficacy between platelet-rich plasma and placebo